Protocol Ledger

NCT04857359 · Phase II/III · TERMINATED

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Interventional Phase II/III clinical trial protocol NCT04857359 sponsored by Addex Pharma in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-06 Enrollment: 25 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04857359
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)25 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04857359
Protocol FieldVerified Registry Value
NCT IdentifierNCT04857359
Consolidated Lead SponsorAddex Pharma
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment25 participants (ACTUAL)
Registered Start Date2021-08-06
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI